SHPHNasdaqPharmaceutical PreparationsUS GAAP · USD

Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals Holdings, Inc. is a U.S.-based discovery and development stage pharmaceutical company focused on novel cancer therapies. The company’s work centers on product candidates designed to improve the effectiveness and delivery of radiation therapy and related oncology treatments.

Kysy yhtiöstä
Liikevoitto (EBIT)−11,9milj. USD
−54,8 %v/v
Nettotulos−11,7milj. USD
−28,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2021–2025

−12,5−10,0−7,5−5,0−2,50,0milj. USD2021: EBIT −1,7 milj. USD20212022: EBIT −2,3 milj. USD20222023: EBIT −5,9 milj. USD20232024: EBIT −7,7 milj. USD20242025: EBIT −12 milj. USD2025−12
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Shuttle Pharmaceuticals Holdings, Inc.

Liiketoiminta

Osuus liikevaihdosta
Oncology drug candidates100 %

Investigational pharmaceutical products designed to treat cancer and improve standard therapies.

Radiation therapy enhancement0 %

Compounds intended to improve the safety, reliability, or effectiveness of radiation treatment.

Clinical development services0 %

Internal development activities supporting preclinical work, trials, and regulatory advancement.

Asiakkaat

Shuttle Pharmaceuticals does not sell commercial products broadly; its primary stakeholders are oncology patients indirectly served through hospitals, cancer centers, and physicians if its candidates are approved. In the development stage, the company’s economic “customers” are effectively clinical investigators, research partners, regulators, and future healthcare providers that would adopt its therapies.

Future oncology treatment providers

Hospitals, cancer centers, and radiation oncology practices that would use approved therapies in patient care.

Clinical trial ecosystem

CROs, trial sites, investigators, and research partners supporting development of Ropidoxuridine and other candidates.

Regulatory and scientific stakeholders

FDA and other oversight bodies, plus academic and clinical collaborators that influence approval and evidence generation.

Strategia

The company’s strategy is to advance a cancer-focused pipeline from discovery into clinical testing, with emphasis on therapies that complement radiation oncology. It also relies on external financing and third-party clinical infrastructure to support development, making capital access and trial execution central to its path forward.

Advance Ropidoxuridine clinical trialsLyhyt aikaväli

Clinical data is the main value driver for a development-stage oncology company.

Maintain financing capacityLyhyt aikaväli

Development programs require ongoing external capital before product revenue exists.

Position the platform around radiation oncologyKeskipitkä aikaväli

A focused therapeutic niche can differentiate the pipeline and support partnering.

Maantiede

The company is headquartered in the United States and conducts its development activities from a U.S. base. Its business is tied to U.S. clinical, regulatory, and financing markets, with no disclosed commercial revenue geography in the provided materials.

Riskit

Shuttle Pharmaceuticals faces the typical risks of a pre-revenue biotech company: clinical failure, regulatory delays, and dependence on external funding. Because the business is centered on a small pipeline and third-party trial execution, setbacks in development or capital access can materially affect its ability to continue operations.

Järjestetty vakavuuden mukaan
Clinical development failureKriittinen

Pipeline value depends on trial results for Ropidoxuridine and related candidates.

Kohdistuu: Lead oncology program

Funding and dilution riskKorkea

The company has no operating revenue and relies on equity or similar financing.

Kohdistuu: Corporate liquidity and development budget

Regulatory approval riskKorkea

Drug candidates must satisfy safety and efficacy requirements before commercialization.

Kohdistuu: FDA and clinical pathway

Third-party execution riskKeskitaso

Trials depend on CROs, clinical sites, and vendors outside direct control.

Kohdistuu: Theradex and other service providers

Kysy Clarifolta: Shuttle Pharmaceuticals Holdings, Inc.

Kirjanpito

Harkinnanvaraiset erät
Research and development expense

Clinical trial, CRO, and regulatory costs are expensed as incurred and drive operating loss.

Vaikutus: Higher trial activity increases reported R&D expense

Fair value of convertible notes

Valuation changes can create non-cash gains or losses unrelated to operations.

Vaikutus: Can materially affect net loss and comparability

Derivative financial instruments

Embedded features and warrants require periodic fair value remeasurement.

Vaikutus: Can cause volatility in other expense

Stock-based compensation

Equity awards are a meaningful non-cash operating cost for early-stage biotech.

Vaikutus: Raises reported expenses without immediate cash outflow

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Mustang Bio, Inc

MBIO · Pharmaceutical Preparations

RAPT Therapeutics, Inc.

Pharmaceutical Preparations

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

Intensity Therapeutics, Inc

INTS · Biological Products, (No Diagnostic Substances)

GT Biopharma, Inc.

GTBP · Pharmaceutical Preparations

Cadrenal Therapeutics, Inc.

CVKD · Pharmaceutical Preparations

Päivitetty: 24.9.2026